Release date: 19 June 2018
Promoter – Financial Intermediary
NIGHTINGALE HEALTH OYLocation
Description
The project concerns investments into research and development (R&D) and related capital expenditure activities in the field of blood analysis, to provide solutions for chronic disease detection and prevention.
Objectives
The proposed transaction will support further development of the promoter's blood analysis platform, enable to generate scientific evidence of clinical utility of the promoter's risk prediction panel and support achieving reimbursement in Europe.
Sector(s)
- Services - Professional, scientific and technical activities
Proposed EIB finance (Approximate amount)
EUR 20 million
Total cost (Approximate amount)
EUR 55 million
Environmental aspects
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Procurement
The promoter is a private company not operating in the utilities sector and which does not have the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Status
Signed - 26/07/2018
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).